The NIH is the premier biomedical research center for the world. Its 27 Institutes and Centers employ approximately 18,000 employees doing a vast array of jobs, all supporting efforts for a healthy nation. For information on the NIH mission, goals, and Institutes visit NIH Overview.
If you have extensive experience in the conduct of clinical trials research and the current treatment of selected solid tumor malignancies (e.g. lung, sarcoma, melanoma, head and neck etc.) AND you want to play a significant role in a dynamic organization, then consider joining the NCI Clinical Investigations Branch! For more information, visit: http://ctep.cancer.gov/branches/cib/default.htm. This position is located in the Department of Health and Human Services (HHS), National Institutes of Health (NIH), National Cancer Institute (NCI), Division of Cancer Treatment and Diagnosis (DCTD), Cancer Therapy Evaluation Program (CTEP), Clinical Investigations Branch (CIB).
The Cancer Therapy Evaluation Program (CTEP) is the Program within DCTD that is responsible for the coordination of the NCIs national cancer clinical trials program. CTEP plans, assesses, and coordinates all aspects of clinical trials pertaining to the development and evaluation of anticancer agents, including NCI supported extramural clinical research programs, NCI intramural treatment programs, and evaluation of treatment methods and effectiveness, and compilation and exchange of data. Within CTEP, CIB oversees the development and evaluation of multimodality anticancer therapies through the sponsorship of clinical trials. As such, it is responsible for the majority of large, extramural, NCI-sponsored cancer clinical trials conducted in the United States. It does this largely through interactions with investigators within NCI-sponsored Clinical Trials Networks as well as other clinical trial organizations and consortia. In addition, in concert with other components of CTEP, CIB participates in developing the research projects preparatory to Phase III studies, including Phase I, II, pilot and laboratory-translational trials.